期刊
JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT
卷 156, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.josat.2023.209209
关键词
Buprenorphine-naloxone; Suboxone; Split dosing; OUD; Treatment retention
In this retrospective analysis, the dosing frequency of sublingual buprenorphine-naloxone was studied to evaluate its impact on the effectiveness of therapy for opioid use disorder. The study found no significant differences in treatment retention rates, medication adherence, adherence to treatment program, and hospital encounters between once daily dosing and split daily dosing groups.
Introduction: In clinical practice, sublingual (SL) buprenorphine-naloxone is prescribed as once daily or split daily dosing for the management of opioid use disorder (OUD). Evidence is lacking that assesses how split daily buprenorphine-naloxone affects OUD outcomes. This study aims to evaluate how the dosing frequency of SL buprenorphine-naloxone impacts therapy effectiveness when treating patients with OUD.Methods: This retrospective analysis included adult outpatients prescribed treatment with SL buprenorphinenaloxone for OUD between July 1, 2016, and March 1, 2020. The study excluded patients with sickle cell disease, recent methadone treatment, or pregnancy. We characterized study groups by dosing frequency, either once daily or split dosing. The study compared retention in treatment, medication adherence, adherence to treatment program, and hospital encounters between groups.Results: The study screened eight-hundred and seven patients, and included 250 patients newly prescribed SL buprenorphine-naloxone. Fifty-seven patients (22.8 %) were prescribed once daily dosing and 193 patients (77.2 %) were prescribed split daily dosing. The study found no significant differences noted in 12-month rates of treatment retention (52.6 % vs. 45.6 %, p = .35). These outcomes remained similar when assessed at three and six months. Within a year of buprenorphine-naloxone initiation, the study found no differences in the percentage of patients with hospitalizations (26.3 % vs. 38.3 %, p = .10), median number of hospitalizations (2 vs. 2), or proportion of days covered by a prescription >= 80 % (93.3 % vs. 92.0 %, p = .82).Conclusions: In this study, patients receiving once daily buprenorphine-naloxone had similar treatment outcomes to patients receiving split dosing. Further controlled studies are necessary to evaluate which patients are more likely to benefit from split dosing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据